Hill Dermaceuticals, Inc® Announces FDA Orphan Drug Designation in Fungal Otitis Externa (Otomycosis)

Sanford, Florida, May 22, 2014 – Hill Dermaceuticals, Inc^®, a privately held pharmaceutical company with 6 NDAs and that develops and manufactures prescription drugs focusing on Dermatologic diseases, announced that the United States Food and Drug Administration (“FDA”) has granted orphan drug designation to its investigational drug for Fungal Otitis Externa (Otomycosis).